` CAPS (Capstone Therapeutics Corp) vs S&P 500 Comparison - Alpha Spread

CAPS
vs
S&P 500

Over the past 12 months, CAPS has underperformed S&P 500, delivering a return of -76% compared to the S&P 500's +15% growth.

Stocks Performance
CAPS vs S&P 500

Loading
CAPS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CAPS vs S&P 500

Performance Gap Between CAPS and GSPC
HIDDEN
Show

Performance By Year
CAPS vs S&P 500

Loading
CAPS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Capstone Therapeutics Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Capstone Therapeutics Corp
Glance View

Market Cap
5.4m USD
Industry
Biotechnology

Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.

CAPS Intrinsic Value
Not Available
Back to Top